CA-ATTACKIQ
20.4.2022 15:02:05 CEST | Business Wire | Press release
AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced a new integration with Vectra®, an AI-driven threat detection and response platform that enables joint customers to detect attacks that have bypassed existing security controls and ensure rapid response to the latest threats.
"In today's hyper-complex threat environment, organizations must think proactively and adopt advanced security capabilities to prevent successful attacks," said Carl Wright, Chief Commercial Officer at AttackIQ. "This integration will allow our customers to validate the efficacy of the Vectra AI platform by utilizing AttackIQ's PCAP replay and related network scenarios to find and fix coverage gaps throughout their security infrastructure before adversaries exploit them."
AttackIQ operates under the "assume breach" mindset, recognizing that it is not a question of if but when an intruder will break past an organization's perimeter defense. Leveraging automated breach and attack simulation technology and the MITRE ATT&CK framework, the AttackIQ Security Optimization Platform enables organizations to measure their security controls performance, identify misconfigurations or gaps in coverage, and focus resources on areas with the highest probability of risk exposure.
"It is exciting to see AttackIQ and Vectra joining forces to help customers enable a proactive, threat-informed defense," said Geert Busse, Head of Next-Gen Solutions Pre Sales EMEA, Westcon. "As key vendors in our Westcon Next Generation Solutions go-to-market strategy, these two organizations are the backbone of our technology pillar, focusing on defense against emerging threats by delivering automation, integration and efficiency that our industry needs to detect and stop the latest generation of Threat Actors."
The Vectra Platform uses security-led artificial intelligence (AI) to power threat detection and response to ensure speed, precision, and efficiency in surfacing and stopping attacks before devastating impact. The platform captures data from network packets and logs that give insight into companies' public cloud and SaaS environment, federated identity, and data center networks. Vectra's patented approach to applying AI to detection analyzes all detection to prioritize threats and map events to MITRE ATT&CK framework without noise and hunting. It further drives appropriate remediation and rapid response through other tools already implemented in your security stack.
The AttackIQ Security Optimization Platform integration with the Vectra Threat Detection and Response Platform is available today.
To learn more about this integration and see it in action register for the May 5th demo here: https://attackiq.com/get-a-demo/weekly-demo/ .
About AttackIQ
AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry's first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free award-winning AttackIQ Academy , open Preactive Security Exchange, and partnership with MITRE Engenuity's Center for Threat-Informed Defense . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .
About Vectra AI
Vectra® is a leader in threat detection and response for hybrid and multi-cloud enterprises. The Vectra platform uses AI to detect threats at speed across public cloud, identity, SaaS applications, and data centers. Only Vectra optimizes AI to detect attacker methods—the TTPs at the heart of all attacks—rather than simplistically alerting on "different". The resulting high-fidelity threat signal and clear context enables security teams to respond to threats sooner and to stop attacks in progress faster. Organizations worldwide rely on Vectra for cybersecurity resilience in the face of dangerous cyber threats and to prevent ransomware, supply chain compromise, identity takeovers, and other cyberattacks from impacting their businesses. For more information, visit vectra.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005006/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye
Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse
Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release
For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
